Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 21:57:100581.
doi: 10.1016/j.ahjo.2025.100581. eCollection 2025 Sep.

Lipoprotein (a) in primary cardiovascular disease prevention is actionable today

Vibhu Parcha  1 , Vera A Bittner  1
Affiliations
Review

Lipoprotein (a) in primary cardiovascular disease prevention is actionable today

Vibhu Parcha et al. Am Heart J Plus. .

Abstract

Lipoprotein(a) [Lp(a)] has emerged as an important, genetically determined, and independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease. Despite growing evidence of its causal role in cardiovascular morbidity and mortality, its actionability in primary prevention remains underrecognized. This review highlights the contemporary scientific foundation supporting early Lp(a) measurement, elucidates its pathogenic mechanisms, evaluates the evolving therapeutic landscape, and proposes a pragmatic clinical framework for integrating Lp(a) into preventive cardiology today. Through clinical vignettes and current data, we argue that identifying elevated Lp(a) can meaningfully guide risk reclassification, intensify modifiable risk management, and inform patient-centered preventive strategies thereby making Lp(a) testing actionable in contemporary primary prevention.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: VB serves on Data and Safety Monitoring Boards for Verve Therapeutics and Eli Lilly; is a site Principal Investigator for Amgen (EVOLVE-MI) and Novartis (ORION-IV); serves as Senior Guest Editor for Circulation (American Heart Association); and is Editor-in-Chief of the ACC Self-Assessment Program (SAP) for the American College of Cardiology. VP has no relevant disclosures of conflicts of interest.

Figures

Fig. 1
Fig. 1
Estimated Lifetime Risk of ASCVD by Baseline Risk and Lp(a) Concentration. Lifetime risk of atherosclerotic cardiovascular disease (ASCVD) is shown across five strata of baseline risk (5 %, 10 %, 15 %, 20 %, and 25 %) as determined by the Joint British Societies (JBS3) Lifetime Risk Estimator. The incremental impact of lipoprotein(a) [Lp(a)] is modeled across plasma concentration categories (<30, 30–50, 51–75, 76–100, and 101–150 mg/dL), assuming a constant hazard ratio for Lp(a) across all baseline risk levels. Risk estimates are derived from a cohort of 415,274 UK Biobank participants of European ancestry. Modified from data presented in Fig. 6 and Supplementary Table 3, as published in the 2022 European Atherosclerosis Society Consensus Statement [12].
Fig. 2A
Fig. 2A
Familial Hypercholesterolemia with Elevated Lp(a).
Fig. 2B
Fig. 2B
Family History of Aortic Stenosis with High Lp(a).
Fig. 2C
Fig. 2C
Family History of Premature Coronary Heart Disease.
Fig. 2D
Fig. 2D
Borderline LDL-C and Elevated Lp(a) in a ‘Low-Risk’ Patient.
Fig. 2E
Fig. 2E
Isolated High Lp(a) Discovered by Screening.
See this image and copyright information in PMC

References

    1. Wong N.D., Fan W., Hu X., Ballantyne C., Hoodgeveen R.C., Tsai M.Y., et al. Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort. J. Am. Coll. Cardiol. 2024;83(16):1511–1525. - PubMed
    1. Wilson D.P., Jacobson T.A., Jones P.H., Koschinsky M.L., McNeal C.J., Nordestgaard B.G., et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J. Clin. Lipidol. 2022;16(5):e77–e95. - PubMed
    1. Reyes-Soffer G., Ginsberg H.N., Berglund L., Duell P.B., Heffron S.P., Kamstrup P.R., et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 2022;42(1):e48–e60. - PMC - PubMed
    1. Bjornson E., Adiels M., Taskinen M.R., Burgess S., Chapman M.J., Packard C.J., et al. Lipoprotein(a) is markedly more Atherogenic than LDL: an apolipoprotein B-based genetic analysis. J. Am. Coll. Cardiol. 2024;83(3):385–395. - PMC - PubMed
    1. Tsimikas S., Marcovina S.M. Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week. J. Am. Coll. Cardiol. 2022;80(9):934–946. - PubMed

LinkOut - more resources